NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|January 2, 2025

Identification, Evaluation, and Management of High-Risk Disease in Early R/R MM

Author(s)Aimee Merino, MD

Aimee Merino, MD, discusses how the identification, evaluation, and management of high-risk disease in early relapsed/refractory multiple myeloma (R/R MM) involves prioritizing specific risk factors, distinguishing functional high-risk patients from those with standard risk, and tailoring treatment strategies accordingly.

Episodes in this series

EP. 1 A 60-Year-Old Man With Early Relapse Multiple Myeloma

EP. 1 A 60-Year-Old Man With Early Relapse Multiple Myeloma

EP. 2 Identification, Evaluation, and Management of High-Risk Disease in Early R/R MM

EP. 2 Identification, Evaluation, and Management of High-Risk Disease in Early R/R MM

EP. 3 Overview of Referral of CAR T for Early R/R Multiple Myeloma

EP. 3 Overview of Referral of CAR T for Early R/R Multiple Myeloma

EP. 4 CARTITUDE-4: Latest Data of Cilta-Cel for Early R/R MM

EP. 4 CARTITUDE-4: Latest Data of Cilta-Cel for Early R/R MM

EP. 5 Navigating Early versus Late Toxicities with CAR T in Myeloma

EP. 5 Navigating Early versus Late Toxicities with CAR T in Myeloma

EP. 6 Alternative Clinical Approaches and Data for Patients not Suitable for 2L CAR T

EP. 6 Alternative Clinical Approaches and Data for Patients not Suitable for 2L CAR T

EP. 7 Future Implications for CAR T in Early RRMM and Treatment Sequencing

EP. 7 Future Implications for CAR T in Early RRMM and Treatment Sequencing

Video content above is prompted by the following:

Let’s discuss the identification, evaluation, and management of high-risk disease in early R/R MM. What characteristics distinguish those patients from others?

What factors do you prioritize when assessing high-risk disease?
How do you define and approach treatment for standard risk patients (ie, HRCAs) vs those who are functional high-risk?

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

Experts featured in this series.

Future Directions in cGVHD Treatment

ByLeyla O. Shune, MD

January 26th 2026

Later-Line and Combination Therapies in cGVHD and Future Directions

ByZachariah DeFilipp, MD

January 23rd 2026

Experts featured in this series.

Sequencing in the cGVHD Treatment Paradigm

ByLeyla O. Shune, MD

January 19th 2026

Second-Line Therapy and Ruxolitinib for cGVHD

ByZachariah DeFilipp, MD

January 16th 2026

Limitations of Steroids and Early Escalation in cGVHD Treatment

ByZachariah DeFilipp, MD

January 16th 2026

Latest CME

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO; Cathy Eng, MD, FACP, FASCO; John P. Leonard, MD

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC

FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC

FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma

Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer

Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC